Myelofibrosis: Biology and treatment options

European Journal of Haematology

Volumn 79, Issue SUPPL. 68, 2007, Pages 13-17

  Cervantes, Francisco ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Allogeneic transplantation; Anaemia; Cytotoxic agents; Janus kinase 2; Myelofibrosis; Myeloproliferative disorders

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; ANDROGEN; ANGIOGENESIS INHIBITOR; BUSULFAN; CORTICOSTEROID DERIVATIVE; CYTOTOXIC AGENT; DANAZOL; FLUDARABINE; HYDROXYUREA; IMATINIB; JANUS KINASE 2; LENALIDOMIDE; MELPHALAN; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PLACEBO; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SEMAXANIB; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THYMOCYTE ANTIBODY; TIPIFARNIB; VASCULOTROPIN; DRUG DERIVATIVE; ERYTHROPOIETIN; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; CD34 SELECTION; CHROMOSOME 13Q; CHROMOSOME 20Q; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; LEUKOCYTOSIS; LOW DRUG DOSE; MORBIDITY; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONING; SOMNOLENCE; SPLENECTOMY; SURVIVAL RATE; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CHRONIC DISEASE; DRUG ANTAGONISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATHOPHYSIOLOGY; REVIEW;

CHRONIC DISEASE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; MYELOFIBROSIS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINAZOLINES; SPLENECTOMY; THALIDOMIDE;

EID: 34548262256     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00937.x     Document Type: Conference Paper

References (32)

1. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999 93 : 2831 8.
2. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999 17 : 2954 70.
3. Castro-Malaspina H. Pathogenesis of myelofibrosis: role of ineffective megakaryopoiesis and megakaryocyte components. Prog Clin Biol Res 1984 154 : 427 54.
4. Le Bousse-Kerdiles MC, Martyre MC. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis. Pathol Biol (Paris) 2001 49 : 153 7.
5. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000 165 : 2271 7.
6. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996 88 : 1013 8.
7. Ahmed A, Chang CC. Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis. Arch Pathol Lab Med 2006 130 : 1133 43.
8. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990 44 : 33 8.
9. Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 1991 77 : 252 4.
10. Arana-Yi C, Quintas-Cardama A, Giles F, Thomas D, Carrasco-Yalan A, Cortes J, Kantarjian H, Verstovsek S. Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 2006 11 : 929 43.
11. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999 106 : 682 8.
12. Cervantes F, varez-Larran A, Domingo A, rellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005 129 : 771 5.
13. Cervantes F, varez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004 127 : 399 403.
14. Cervantes F, varez-Larran A, Hernandez-Boluda JC, Sureda A, Granell M, Vallansot R, Besses C, Montserrat E. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006 134 : 184 6.
15. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003 102 : 3912 8.
16. Guardiola P, Anderson JE, Gluckman E. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000 343 : 659 60.
17. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005 105 : 4115 9.
18. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002 99 : 2255 8.
19. Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005 128 : 690 7.
20. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001 98 : 586 93.
21. Barosi G, Elliott M, Canepa L, Ballerini F, Piccaluga PP, Visani G, Marchetti M, Pozzato G, Zorat F, Tefferi A. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002 43 : 2301 7.
22. Abgrall JF, Guibaud I, Bastie JN, et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006 91 : 1027 32.
23. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004 22 : 424 31.
24. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003 101 : 2534 41.
25. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 108 : 1158 64.
26. Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003 97 : 2760 6.
27. Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H, Therkildsen MH, Ralfkiaer E. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol 2003 74 : 238 42.
28. Stagno F, Consoli C, Mannino F, Guglielmo P, Giustolisi R. Successful treatment of advanced idiopathic myelofibrosis with imatinib mesylate. Eur J Haematol 2004 73 : 147 8.
29. Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 2002 99 : 3854 6.
30. Giles FJ, Cooper MA, Silverman L, et al. Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer 2003 97 : 1920 8.
31. Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003 17 : 849 55.
32. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003 101 : 1692 7.